Background: While the typical features of large cholangiocarcinomas have been described extensively and are known to radiologists, atypical cholangiocarcinomas are not as well known and radiologists should be more aware of their features. Due to the increasing numbers of cross-sectional imaging studies performed for various reasons, cholangiocarcinomas may be more frequently detected incidentally when small, before they become symptomatic, and might be mistaken for other liver lesions. We studied the appearance of misdiagnosed cholangiocarcinomas.
Materials And Methods: This is a HIPAA-compliant, IRB-approved retrospective study. Our institutional database and teaching files were searched for cases of cholangiocarcinomas diagnosed between 2004 and 2014 that were initially misdiagnosed or considered indeterminate lesions on MRI or CT. Clinical data and radiological findings were collected. History of malignancy and risk factors for cholangiocarcinoma were recorded. The initial reported diagnosis and time to the correct diagnosis were noted, and the lesions were evaluated for size, enhancement, T1/T2 signal, diffusion restriction, ADC value, capsular retraction, biliary dilatation and the presence of satellite nodules.
Results: Nine examples of cholangiocarcinoma that met our inclusion criteria were identified: seven men and two women. All were small, with a mean size of 2.2 cm upon initial diagnosis. All showed a hypervascular pattern of enhancement without washout. Imaging features that are described in the literature as typical for cholangiocarcinomas, such as capsular retraction, satellite nodules, and peripheral biliary dilatation, were not seen.
Conclusion: Cholangiocarcinomas can be misdiagnosed when they are small and hypervascular. This atypical hypervascular appearance is rare, and may mimic benign liver lesions and other malignant lesions, especially when small. Awareness of the confounding imaging features of these tumors should lead to a more meticulous evaluation of small hypervascular lesions, and may minimize the risk of misdiagnosing early-stage cholangiocarcinomas.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00261-015-0480-2 | DOI Listing |
Arq Bras Cir Dig
January 2025
Mongi Slim Hospital, Department of Pathology - Marsa, Tuni, Tunísia.
Background: Hepatocellular carcinoma (HCC) encompasses rare variants like chromophobe hepatocellular carcinoma (CHCC) characterized by distinct histological features and molecular profiles.
Case Report: A 56-year-old male with chronic hepatitis C, presenting pain in the right hypochondrium. Imaging revealed a solitary liver lesion, subsequently resected and histologically diagnosed as HCC.
World J Gastroenterol
January 2025
Department of Gastroenterology, Dayanand Medical College and Hospital, Ludhiana 141001, Punjab, India.
This letter critically evaluates Jiang 's article on the differentiation of benign and malignant liver lesions using Emax and platelet count. Despite notable findings, significant methodological and interpretative limitations are identified. The study lacks detailed assay conditions for Emax measurement, employs inadequate statistical methods without robust multivariate analysis, and does not provide clinically relevant threshold values.
View Article and Find Full Text PDFPathol Oncol Res
January 2025
Department of Nuclear Medicine, Prof. Dr. Cemil Taşcıoğlu City Hospital, University of Health Sciences, Istanbul, Türkiye.
Background And Objectives: This study aims to evaluate the correlation between Tumor-Infiltrating Lymphocyte (TIL) levels and Fluorine-18 fluorodeoxyglucose (F-FDG) metabolic parameters, including spleen and bone marrow FDG uptake and tumor heterogeneity in non-luminal breast cancers (NLBC), and to elucidate their association with survival outcomes.
Methods: We retrospectively analyzed data from 100 females with stage 2-4 NLBC who underwent pretreatment F-FDG Positron emission tomography-computed tomography (PET/CT). TIL was scored based on Hematoxylin-Eosin-stained specimens and F-FDG PET metabolic parameters, including maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), metabolic tumor volume (MTV), total lesion glycolysis (TLG), liver, spleen, and bone marrow FDG uptake were calculated.
Discov Immunol
December 2024
Laboratory of Functional Genomics and Medicine, Division of Biological Science, Nara Institute of Science and Technology (NAIST), Ikoma-shi, Nara, Japan.
Introduction: Programmed death-1 (PD-1) is a negative regulator of immune responses. Upon deletion of PD-1 in mice, symptoms of autoimmunity developed only after they got old. In a model experiment in cancer immunotherapy, PD-1 was shown to prevent cytotoxic T lymphocytes from attacking cancer cells that expressed neoantigens derived from genome mutations.
View Article and Find Full Text PDFFront Oncol
January 2025
Department of Radiology, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Background: In the realm of breast cancer diagnosis and treatment, accurately discerning molecular subtypes is of paramount importance, especially when aiming to avoid invasive tests. The updated guidelines for diagnosing and treating HER2 positive advanced breast cancer, as presented at the 2021 National Breast Cancer Conference and the Annual Meeting of the Chinese Society of Clinical Oncology, highlight the significance of this approach. A new generation of drug-antibody combinations has emerged, expanding the array of treatment options for HER2 positive advanced breast cancer and significantly improving patient survival rates.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!